INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY
Lists
Only you see this
Abstract
Intravitreal bevacizumab is well tolerated and improves best-corrected visual acuity in choroidal neovascularization secondary to punctate inner choroidopathy over a 12-month period.
BibTeX
@inproceedings{zhang2012intravitreal,
author = {Han Zhang and Zheli Liu and Peng Sun and Feng Gu},
title = {{INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY}},
booktitle = {Retina},
year = {2012},
doi = {10.1097/iae.0b013e318242b9da},
}Loading related content...